Euthymics Bioscience, Inc. Completes Enrollment in TRIADE, Its Advanced Trial of Amitifadine for Major Depressive Disorder
10/11/2012 10:09:55 AM
More...
|
Euthymics Bioscience, Inc. Initiates Clinical Trial for New Drug Targeted for Adult Attention Deficit Hyperactivity Disorder (ADHD)
3/22/2012 6:35:07 AM
More...
|
Euthymics Bioscience, Inc. Presents Data That Support Advancing EB-1020 into Clinical Trials for Adult ADHD
12/7/2011 6:35:32 AM
More...
|
Euthymics Bioscience, Inc. Appoints Dr. Randall Marshall, Leader in the Psychiatric Field, as Executive Director, Medical Affairs
11/9/2011 7:24:12 AM
More...
|
Euthymics Bioscience, Inc. Appoints Biotech Industry Veteran Thomas A. Shea as CFO and Announces Additional Senior Management Appointments
6/28/2011 11:32:24 AM
More...
|
Euthymics Bioscience, Inc. Initiates Triade Trial for Major Depression
3/14/2011 9:16:38 AM
More...
|
Euthymics Bioscience, Inc. Bumps Series A to $28 Million
3/9/2011 6:31:07 AM
More...
|
Euthymics Bioscience, Inc. Presents Phase II Data for EB-1010 in Major Depression at ACNP Annual Meeting
12/8/2010 8:51:33 AM
More...
|
Euthymics Bioscience, Inc. Appoints Industry Veterans Dr. Pierre Tran, Joan Manthis and William Pappafotopoulos to Senior Management Team
8/18/2010 9:14:52 AM
More...
|
Euthymics Bioscience, Inc. Closes $24 Million Series A Financing and Completes Acquisition of DOV Pharmaceutical
7/22/2010 6:32:38 AM
More...
|
|